Latest Headlines

Latest Headlines

Otsuka, Horizon team up on early-stage development

Horizon Discovery, which makes its money providing development expertise to drugmakers, has signed a deal with Otsuka Pharmaceutical to apply its technology to some early-phase treatments.

Bayer drafts Otsuka exec to lead pharma biz to big growth

Bayer's pharma division has a new president with a big task ahead of him. A week after the company announced its current leader, Andreas Fibig, would jump ship, Bayer says it's chosen an Otsuka Pharmaceutical executive to take the post.

Lundbeck teams with Otsuka on Alzheimer's vaccine development

The vaccine, which is designed to work through early inhibition of amyloid beta depositions, is due to enter Phase I trials next year.

Activist investor fumes over Otsuka bid for Astex

It's a "he said, she said" situation over the true value of Astex Pharmaceuticals. An activist shareholder has thrown up a roadblock for a proposed $886 million bid from Otsuka that it thinks is too low, accusing Astex of failing to reach out to all potential bidders--claims the company denies.

Glaxo, Roche, J&J and others score backing on big day for EU regulator

Friday, the EU's Committee for Medicinal Products for Human Use (CHMP) recommended 11 new drugs for a variety of diseases--the most nods it's given in a single meeting all year.

Otsuka bags Astex cancer drug programs, R&D ops for $886M

Just a few days after Astex reported positive mid-stage data on a lead cancer therapy, Japan's Otsuka has snapped up the U.S. biotech and its slate of experimental cancer drugs for $886 million cash. Astex shares soared yesterday afternoon as the news spread ahead of the official announcement.

Lundbeck, Otsuka tout improved cognition in mid-stage Alzheimer's study

Lundbeck and Otsuka are quickly ramping up a 3,000-patient Phase III study for an experimental Alzheimer's drug after claiming success in improving cognition among a group of patients taking the treatment alongside donepezil for 24 weeks in a Phase II trial.

Headed into PhIII, Lundbeck scores $825M Alzheimer's drug pact with Otsuka

Building on an earlier alliance, Otsuka has gained co-development and co-promotion rights in the U.S., Japan and Europe for Lu AE58054, an experimental Alzheimer's drug now in position for a looming pivotal program.

GW Pharma IDs promising epilepsy drug in cannabis

GW Pharmaceuticals, the U.K. biotech which is commercializing a cannabis-based drug for multiple sclerosis, says their research collaboration with Otsuka has produced a promising new drug candidate for epilepsy.

Lundbeck, Otsuka scramble to get antipsychotic back on FDA track

Lundbeck and its partner Otsuka have put their bid for an approval of their long-acting version of the antipsychotic drug Abilify back on the regulatory track. The partners on aripiprazole say that the FDA has accepted their resubmission for the treatment and set a PDUFA deadline for the end of February in 2013.